Characterization of the novel HLA-B*15:514 allele in a French hematopoietic stem cell donor.


Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
02 2021
Historique:
received: 04 11 2020
revised: 09 11 2020
accepted: 10 11 2020
pubmed: 14 11 2020
medline: 6 7 2021
entrez: 13 11 2020
Statut: ppublish

Résumé

The novel HLA-B*15:514 allele was characterized using two next-generation sequencing technologies.

Identifiants

pubmed: 33184986
doi: 10.1111/tan.14137
doi:

Substances chimiques

HLA-B Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

143-145

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Robinson J, Barker DJ, Georgiou X, Ma C, Flicek P, Marsh SGE. IPD-IGT/HLA Database. Nucleic Acids Res. 2020;48:D948-D955.
Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system. Tissue Antigens. 2010;75:291-455.

Auteurs

Céline Dard (C)

Department of Biology and Therapies, Histocompatibility Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France.

Ornella Senoussi (O)

Department of Biology and Therapies, Histocompatibility Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France.

Stéphane Buhler (S)

Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Switzerland.

Béatrice Bardy (B)

Department of Biology and Therapies, Histocompatibility Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France.

Dominique Masson (D)

Department of Biology and Therapies, Histocompatibility Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH